Teva Pharmaceutical Industries Ltd. (TEVA)

8.57
0.07 0.81
NYSE : Health Technology
Prev Close 8.64
Open 8.54
Day Low/High 8.46 / 8.72
52 Wk Low/High 6.25 / 13.76
Volume 7.23M
Avg Volume 10.87M
Exchange NYSE
Shares Outstanding 1.10B
Market Cap 12.57B
EPS -0.90
P/E Ratio 864.00
Div & Yield N.A. (N.A)
Pfizer and Allergan: Why a Merger Makes Sense

Pfizer and Allergan: Why a Merger Makes Sense

Reports of merger talks have been confirmed, and we believe the two pharma giants would both benefit from the deal.

Eagle Pharmaceuticals Ready to Soar Again

Eagle Pharmaceuticals Ready to Soar Again

After flying high most of the year, the biopharma company is back on my radar.

Plenty of Good News -- If You Look

Plenty of Good News -- If You Look

Not all growth is hated today.

Drug Stocks' Earnings Power Won't Go Away

Before you sell them, ask yourself at what multiple you sell.

Why I'm Adding to My Biotech Positions

Why I'm Adding to My Biotech Positions

I'll continue to add to Amgen, Teva and AbbVie incrementally as recent selloffs seem unwarranted.

Already a Winner, Teva Gets Even Better

Already a Winner, Teva Gets Even Better

Management team and acquisitions help make pharma company a buy.

Novice Trade: TEVA Follow the Leader

Novice Trade: TEVA Follow the Leader

Sometimes it pays to follow the leader. I am going to piggy back the call buyers and buy at-the-money calls in Teva Pharmaceutical.

Bluebird, Pacira Pharmaceuticals Gain Steam in Burgeoning Life Science Space

Bluebird, Pacira Pharmaceuticals Gain Steam in Burgeoning Life Science Space

Investors are most excited about Bluebird Bio (BLUE) and Pacira Pharmaceuticals (PCRX), according to Wedbush Securities, which is holding its annual healthcare investment conference in New York.

Allergan Beats Estimates, Company to Update Guidance Next Quarter

Allergan Beats Estimates, Company to Update Guidance Next Quarter

Drugmaker Allergan is putting off issuing guidance for future quarters following the company's announcement last week that it's selling its generic drug business to Teva Pharmaceuticals.

Jim Cramer: Allergan Is a Favorite Stock, Teva Deal Was 'Incredible'

Jim Cramer: Allergan Is a Favorite Stock, Teva Deal Was 'Incredible'

Jim Cramer, portfolio manager of Action Alerts PLUS, and research director Jack Mohr sat down to talk about their ‘favorite company in the portfolio:’ Allergan.

Day Ahead: FOMC Aftermath; Earnings Continue

Day Ahead: FOMC Aftermath; Earnings Continue

There is building consensus around a September rate hike.

Jensen's Morning Musings

I'm happy as always to be standing in for Doug Kass on the Daily Diary. Premarket futures are currently pointing to a slight opening rise. Let's see if we can build on yesterday's rally after previously seeing five straight declining sessions.  Over...

Teva Makes Right Choice, Baidu Looks Weak, Yelp Gets Own Review

Teva Makes Right Choice, Baidu Looks Weak, Yelp Gets Own Review

In Tuesday’s Analysts' Actions, Wall Street firms review Teva Pharmaceutical Industries (TEVA), Baidu (BIDU), and Yelp (YELP).

Teva upgraded at BMO

Mylan Shares Tank After Teva Pharmaceutical Nixes Takeover Bid

Mylan Shares Tank After Teva Pharmaceutical Nixes Takeover Bid

Pharmaceutical giant Mylan (MYL) was the worst performing stock in the S&P 500 on Monday, making it TheStreet's Move of the Day.

Allergan Jumps, Mylan Slumps After Teva Deal; Stocks Slide

Allergan Jumps, Mylan Slumps After Teva Deal; Stocks Slide

Allergan (AGN) was the best performer on the S&P 500 Monday after Teva Pharmaceuticals (TEVA) agreed to buy its generic-drug business for more than $40 billion.

Cramer Will Be Watching Twitter and Gilead Earnings on Tuesday

Cramer Will Be Watching Twitter and Gilead Earnings on Tuesday

Jim Cramer is watching Twitter (TWTR) as the social media giant releases earnings for its second quarter on Tuesday, July 28th after the market’s closing bell.

Tread Carefully in the Market

Tread Carefully in the Market

This week could easily bring additional selling.

Cramer's Charitable Trust: We Love This Possible Allergan Deal

Cramer's Charitable Trust: We Love This Possible Allergan Deal

And we are raising our price target on AGN.

Alibaba, JD.com Drop on Chinese Market Slump; Stocks Pare Losses

Alibaba, JD.com Drop on Chinese Market Slump; Stocks Pare Losses

U.S.-listed Chinese stocks were under pressure after China's stock market fell at the fastest pace since 2007 on Monday.

Chinese Stocks Post Biggest One-Day Loss in Eight Years

And four other things you need to know now.

Futures Start Mixed With Fed and GDP on Tap

Futures Start Mixed With Fed and GDP on Tap

Two tech companies in Jim Cramer's charitable trust report as well.

Drugmaker Mallinckrodt Looks Very Healthy

Drugmaker Mallinckrodt Looks Very Healthy

Pharmaceutical firm's chart shows a likely move to the upside.

That Was the Week That Was

That Was the Week That Was

Let's review.

Teva Testing Channel Resistance

Teva Testing Channel Resistance

TEVA is a long candidate after a close in upper-candle range above the channel top.

Chinese Stocks Go Down Again Despite Official Measures

And four other things you need to know now.

Rising Rates Won’t Slow Deal Flow Says Kellner Fund Manager

Rising Rates Won’t Slow Deal Flow Says Kellner Fund Manager

Deal flow has been massive in the first half of 2015 from healthcare to technology to insurance.

Grading the Daily Bear Charts for June

Grading the Daily Bear Charts for June

They've done well considering market had a slightly negative month.

Bear Charts of the Day: Teva, Union Pacific

Bear Charts of the Day: Teva, Union Pacific

More names, including some surprises, showing up on bearish scans.

Don’t Ignore Undervalued Israeli Stocks Says BlueStar CIO

Don’t Ignore Undervalued Israeli Stocks Says BlueStar CIO

Israel’s economy is predicted to grow well over 3% in 2015 and its stock market is far outperforming the S&P 500 so far this year.